October 13th 2024
Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.
September 30th 2024
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Data Support 177Lu-PSMA-617 Vs Cabazitaxel in Metastatic Prostate Cancer
December 21st 2023While the overall survival between patients receiving cabazitaxel and those receiving Lu-PSMA-617 had negligible difference, the results of the phase 2 TheraP trial supports the use of Lu-PSMA-617 as an alternative treatment for prostate cancer.
Docetaxel/SOC Significantly Reduces Mortality in Low PSA Prostate Cancer
November 7th 2023Docetaxel plus standard of care may be beneficial among patients with prostate cancer and low prostate-specific antigen levels who do not have any highly effective treatment options, says Anthony D’ Amico, MD, PhD.
MAGNITUDE Trial Highlights OS Benefit with Niraparib Combo in BRCA+ mCRPC
October 22nd 2023Data from the MAGNITUDE trial support the positive benefit/risk profile of niraparib plus abiraterone acetate and prednisone as a treatment for those with BRCA-mutated metastatic castration-resistant prostate cancer.
FDA Gives Priority Review to Enzalutamide in Non-Metastatic HSPC
August 23rd 2023The FDA sets a Prescription Drug User Fee Act date in the fourth quarter of 2023 for its decision regarding enzalutamide as a treatment for those with non-metastatic hormone-sensitive prostate cancer with a high-risk of biochemical recurrence.
FDA Approves FoundationOne CDx for Niraparib/Abiraterone in BRCA+ mCRPC
August 17th 2023The FDA companion diagnostic designation for FoundationOne CDx may improve access to treatment with niraparib/abiraterone acetate dual action tablets in those with metastatic castration-resistant prostate cancer harboring a BRCA mutation.